2026 Q2 - tulosraportti
49 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,16%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 2 | - | - | ||
| 73 | - | - | ||
| 1 | - | - | ||
| 8 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·12 min sittenA rotten system. Denmark does not live by punishing production and investment. We live by skilled companies, a strong private labor market, and people who dare to take risks. When you heavily tax labor, companies, dividends, and capital, e.g., Novo, which is taxed with three layers of corporate tax, dividend tax, and share income tax, but at the same time make passive investment more favorable, you precisely weaken the dynamism that finances the large welfare society in the Kingdom of Denmark. If we want to preserve the welfare society, the tax system and the Christiansborg politicians must reward activity, not passivity.
·40 min sittenTo hold a company that yields a direct return of 4-5%, while also being the best in a growth market, is a privilege few have. I cannot understand why the stock is falling. In the worst case, one can rely on a stable dividend.
·40 min sittenShould I throw in the towel .....🙂....and buy here at 256-257ish? I'm starting to get a bit nervous that it won't reach 250 where I've had a buy order for 1000 units for almost a month now. It seems like something is keeping it up, and I'm afraid it will suddenly take off to 280.I have actually deleted my order now and placed an order for 255,500 pcs, and in 1 month I will buy again. Then that's also the end of more funds in novo. Vestas and nkt should also get some 🙂
·44 min sittenI find it strange that the Novo stock took another big hit downwards due to expectations of lower growth. But with a P/E of around 10 and a dividend of 4.1 %, it is already trading as a value stock. Why does the stock react so negatively to lower growth expectations when it is no longer trading at a high growth premium? To me, this suggests a bit of an overreaction. I topped up, even though Novo Nordisk is already my largest position. Time will tell if that was foolish. That's also the fun thing about stocks. Nothing is black and white.Your 13% NN does not seem to weigh visibly much in your portfolio. The 10% loss, however, is considerable!
·52 min sittenMy point is that the pill version is not only interesting as a treatment, but also because in practice it can extend patent protection by approximately five years. This is important to me as a shareholder in Novo Nordisk, because a longer patent period can strengthen the company's future earnings and competitive position. At the same time, it appears that the pill version has tailwinds and could become an important part of future treatment for severe obesity. Novo Nordisk already has one tablet on the market, and several new tablet treatments are on the way. According to the article, Novo Nordisk has four tablets on the way for severe obesity: https://proinvestor.com/nyheder/novo-har-flere-tabletter-paa-vej-mod-svaer-overvaegt-1789987755213 This also speaks to a clear consumer trend: Many patients will likely prefer a pill over an injection. https://proinvestor.com/nyheder/novo-har-flere-tabletter-paa-vej-mod-svaer-overvaegt-1789987755213
That's true enough, but I wonder if there aren't other technologies than SNAC being worked on, I would think so, and that's probably why no special protection via SNAC is accounted for.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 299 611 | 1 299 611 | 0 | 0 |
| DCAR | 200 000 | 200 000 | 0 | 200 000 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 299 611 | 1 299 611 | 0 | 0 |
| DCAR | 200 000 | 200 000 | 0 | 200 000 |
2026 Q2 - tulosraportti
49 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,16%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 min sittenA rotten system. Denmark does not live by punishing production and investment. We live by skilled companies, a strong private labor market, and people who dare to take risks. When you heavily tax labor, companies, dividends, and capital, e.g., Novo, which is taxed with three layers of corporate tax, dividend tax, and share income tax, but at the same time make passive investment more favorable, you precisely weaken the dynamism that finances the large welfare society in the Kingdom of Denmark. If we want to preserve the welfare society, the tax system and the Christiansborg politicians must reward activity, not passivity.
- ·40 min sittenTo hold a company that yields a direct return of 4-5%, while also being the best in a growth market, is a privilege few have. I cannot understand why the stock is falling. In the worst case, one can rely on a stable dividend.
- ·40 min sittenShould I throw in the towel .....🙂....and buy here at 256-257ish? I'm starting to get a bit nervous that it won't reach 250 where I've had a buy order for 1000 units for almost a month now. It seems like something is keeping it up, and I'm afraid it will suddenly take off to 280.I have actually deleted my order now and placed an order for 255,500 pcs, and in 1 month I will buy again. Then that's also the end of more funds in novo. Vestas and nkt should also get some 🙂
- ·44 min sittenI find it strange that the Novo stock took another big hit downwards due to expectations of lower growth. But with a P/E of around 10 and a dividend of 4.1 %, it is already trading as a value stock. Why does the stock react so negatively to lower growth expectations when it is no longer trading at a high growth premium? To me, this suggests a bit of an overreaction. I topped up, even though Novo Nordisk is already my largest position. Time will tell if that was foolish. That's also the fun thing about stocks. Nothing is black and white.Your 13% NN does not seem to weigh visibly much in your portfolio. The 10% loss, however, is considerable!
- ·52 min sittenMy point is that the pill version is not only interesting as a treatment, but also because in practice it can extend patent protection by approximately five years. This is important to me as a shareholder in Novo Nordisk, because a longer patent period can strengthen the company's future earnings and competitive position. At the same time, it appears that the pill version has tailwinds and could become an important part of future treatment for severe obesity. Novo Nordisk already has one tablet on the market, and several new tablet treatments are on the way. According to the article, Novo Nordisk has four tablets on the way for severe obesity: https://proinvestor.com/nyheder/novo-har-flere-tabletter-paa-vej-mod-svaer-overvaegt-1789987755213 This also speaks to a clear consumer trend: Many patients will likely prefer a pill over an injection. https://proinvestor.com/nyheder/novo-har-flere-tabletter-paa-vej-mod-svaer-overvaegt-1789987755213That's true enough, but I wonder if there aren't other technologies than SNAC being worked on, I would think so, and that's probably why no special protection via SNAC is accounted for.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 2 | - | - | ||
| 73 | - | - | ||
| 1 | - | - | ||
| 8 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 299 611 | 1 299 611 | 0 | 0 |
| DCAR | 200 000 | 200 000 | 0 | 200 000 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 299 611 | 1 299 611 | 0 | 0 |
| DCAR | 200 000 | 200 000 | 0 | 200 000 |
2026 Q2 - tulosraportti
49 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
3,75 DKK/osake
Viimeisin osinko
4,16%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 min sittenA rotten system. Denmark does not live by punishing production and investment. We live by skilled companies, a strong private labor market, and people who dare to take risks. When you heavily tax labor, companies, dividends, and capital, e.g., Novo, which is taxed with three layers of corporate tax, dividend tax, and share income tax, but at the same time make passive investment more favorable, you precisely weaken the dynamism that finances the large welfare society in the Kingdom of Denmark. If we want to preserve the welfare society, the tax system and the Christiansborg politicians must reward activity, not passivity.
- ·40 min sittenTo hold a company that yields a direct return of 4-5%, while also being the best in a growth market, is a privilege few have. I cannot understand why the stock is falling. In the worst case, one can rely on a stable dividend.
- ·40 min sittenShould I throw in the towel .....🙂....and buy here at 256-257ish? I'm starting to get a bit nervous that it won't reach 250 where I've had a buy order for 1000 units for almost a month now. It seems like something is keeping it up, and I'm afraid it will suddenly take off to 280.I have actually deleted my order now and placed an order for 255,500 pcs, and in 1 month I will buy again. Then that's also the end of more funds in novo. Vestas and nkt should also get some 🙂
- ·44 min sittenI find it strange that the Novo stock took another big hit downwards due to expectations of lower growth. But with a P/E of around 10 and a dividend of 4.1 %, it is already trading as a value stock. Why does the stock react so negatively to lower growth expectations when it is no longer trading at a high growth premium? To me, this suggests a bit of an overreaction. I topped up, even though Novo Nordisk is already my largest position. Time will tell if that was foolish. That's also the fun thing about stocks. Nothing is black and white.Your 13% NN does not seem to weigh visibly much in your portfolio. The 10% loss, however, is considerable!
- ·52 min sittenMy point is that the pill version is not only interesting as a treatment, but also because in practice it can extend patent protection by approximately five years. This is important to me as a shareholder in Novo Nordisk, because a longer patent period can strengthen the company's future earnings and competitive position. At the same time, it appears that the pill version has tailwinds and could become an important part of future treatment for severe obesity. Novo Nordisk already has one tablet on the market, and several new tablet treatments are on the way. According to the article, Novo Nordisk has four tablets on the way for severe obesity: https://proinvestor.com/nyheder/novo-har-flere-tabletter-paa-vej-mod-svaer-overvaegt-1789987755213 This also speaks to a clear consumer trend: Many patients will likely prefer a pill over an injection. https://proinvestor.com/nyheder/novo-har-flere-tabletter-paa-vej-mod-svaer-overvaegt-1789987755213That's true enough, but I wonder if there aren't other technologies than SNAC being worked on, I would think so, and that's probably why no special protection via SNAC is accounted for.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 2 | - | - | ||
| 73 | - | - | ||
| 1 | - | - | ||
| 8 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 299 611 | 1 299 611 | 0 | 0 |
| DCAR | 200 000 | 200 000 | 0 | 200 000 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 299 611 | 1 299 611 | 0 | 0 |
| DCAR | 200 000 | 200 000 | 0 | 200 000 |